Мукорегуляторные препараты в терапии кашля при респираторной патологии у детей (обзор литературы)
DOI:
https://doi.org/10.15574/SP.2015.72.57Ключевые слова:
кашель, дети, мукоактивные препараты, карбоцистеин, ФлюдитекАннотация
Кашель является наиболее частым симптомом респираторных заболеваний у детей. Симптом кашля требует дифференцированного подхода в выборе лечебной тактики с учетом этиологии, возрастных особенностей респираторного тракта у детей и патогенетических механизмов развития кашля. В статье представлен обзор литературы по использованию мукорегуляторного препарата Флюдитек при заболеваниях органов дыхания у детей.
Библиографические ссылки
Adaptovana klinichna nastanova, zasnovana na dokazakh «Kashel». Nakaz MOZ Ukrainy vid 08.06.2015 №327 «Pro zatverdzhennia ta vprovadzhennia medyko#tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry kashli».
Andreichyn MA, Malyi VP, Kovalchuk LIa ta in. 2011. Adapt klin nastanova. Hostri respiratorni virusni infektsii. Navchalnyi posibnyk. Za red MA Andreichyna, VP Maloho. Ternopil, TDMU; Ukrmedknyha: 303.
Balyasinskaya GL, Lyumanova SR, Landa RI. 2006. Znachenie mukoaktivnoy terapii v lechenii ostryih sinusitov u detey. Ros otorinolaringol. 6(25): 84—86.
Balyasinskaya GL, Timakov EYu. 2010. Opyit primeneniya karbotsnstenna v terapii detey rannego vozrasta s ostryim obstruktivnyim bronhitom. Pulmonol detskogo vozrasta: problemyi i resheniya. 10: 102—104.
Bereznyakov IG. 2007. Kashel: ot diagnoza k lecheniyu. Novosti meditsinyi i farmatsii. 5(209).
Belih NA. 2012. Experience with the carbocysteine application in children with acute respiratory diseases. Sovremennaya pediatriya. 5: 74—78.
Boiko NS, Marushko YuV. 2012. Experience of carbocisteine use in pediatric practice. Sovremennaya pediatriya. 7: 115—120.
Boikova NE, Tarasova GD. 2011. Mucolytic treatment during the upper respiratory tract diseases in smoking teens. Sovremennaya pediatriya. 2(36): 1—4.
Geppe NA, Malahov AB. 1999. Mukoliticheskie i protivokashlevyie sredstva v praktike pediatra (lektsiya). Det doktor. 4: 42—45.
Geppe NA, Snegotskaya MN, Nikitenko AA. 2007. Atsetiltsistein v lechenii kashlya u detey. Consilium Medicum. 2: 35—40.
Geppe NA, Snegotskaya MN. 2004. Mesto mukoregulyatorov v terapii bronholegochnyih zabolevaniy u detey. Farmateka. 17: 35—39.
Globalnyiy plan VOZ po podgotovke k borbe s grippom. WHO/CDS/CSR/GIP/2012/5.WHO/CDS/CSR/GIP/2012/5.
Dronova OI. 2007. Hronicheskaya obstruktivnaya bolezn legkih: aktsent na mukolitiki. Rus med zhurn. 15(18).
Ermakova IN, Mizernitskiy YuL. 2008. Effektivnost mukoregulyatorov v terapii ostryih respiratornyih infektsiy u detey s bronhialnoy astmoy. Consilium medicum. 2: 73-75
Ermakova IN, Mizernitskiy YuL. 2012. Karbotsistein (Flyuditek) v kompleksnoy terapii retsidiviruyuschih respiratornyih infektsiy nizhnih dyihatelnyih putey u detey. Zemskiy Vrach. 5(16): 17—21.
Ermakova IN, Mizernitskiy YuL, Krivosheina EL. 2009. Vliyanie mukoregulyatorov na sostoyanie mestnogo immuniteta dyihatelnyih putey i uroven mezhkletochnyih vzaimodeystviy pri kompleksnom lechenii ORVI u detey s bronhialnoy astmoy. Vopr prakt pediatrii. 4: 17—21.
Ershova IB, Kovalenko IA, Kunegina EH. 2006. ORZ u detey. Differentsirovannaya terapiya. Chasopisi. 2.
Zaytseva OV. 2009. Lechenie kashlya u detey. Consilium medicum. Pediatriya (Pril). 3: 76—80.
Zaytseva OV. 2004. Mukoliticheskie preparatyi v terapii bolezney organov dyihaniya u detey: sovremennyiy vzglyad na problemu. Pulmonologiya detskogo vozrasta: problemyi i resheniya. 4: 71—82.
Zaytseva OV. 2009.Ratsionalnyiy vyibor mukoliticheskoy terapii v lechenii bolezney organov dyihaniya u detey. Rus med zhurnal. 17(19): 1217—1222.
Zaharova IN, Dmitrieva YuA. 2010. Kashel u detey: differentsialnaya diagnostika i taktika lecheniya. Consilium Medicum Ukraina. 1: 31—37.
Zaharova IN, Dmitrieva YuA, Zaplatnikov AL. 2010. Differentsirovannyiy podhod k terapii kashlya u detey. Consilium medicum. Pediatriya (Pril). 3: 48—52.
Ilenko LI, Garaschenko TI, Patudin AV. 2007. Protivokashlevaya i mukoreguliruyuschaya terapiya u detey: traditsionnyie i netraditsionnyie podhodyi k lecheniyu. M, MIA.
Instruktsiya primeneniya preparata Flyuditek sirop 2%, 5% po 125 ml vo flakonah №1. http://www.drlz.com.ua
Katilov AV, Mazulov AV, Dmitriev DV. 2008. Klinicheskaya diagnostika hronicheskogo kashlya u detey. KlInIchna ImunologIya AlergologIya InfektologIya. 5/2. http://kiai.com.ua/article/234.html.
Klyachkina IL. 2011. Esche raz o mukolitikah. Consilium Medicum Ukraina. 1.
Kompendium 2015. Lekarstvennyie preparatyi (2015). http://compendium.com.ua/info/2296/
Korovina NA i soavt. 2002. Protivokashlevyie i otharkivayuschie lekarstvennyie sredstva v praktike vracha-pediatra: ratsionalnyiy vyibor i taktika primeneniya. Posobie dlya vrachey. M: 40.
Mavrodiy VM. 2012. Allergologiya: ustranenie giperchuvstvitelnosti. Rekomendatsii dlya desensibiliziruyusch vrachey. Assots Semeynyih vrachey Odes Regiona. Donetsk, Zaslavskiy AYu: 111.
Maidannyk VH, Burlai VH, Hnateiko OZ, Duka KD, Nachytailo YuM, Khaitovych MV. 2012. Propedevtychna pediatriia. Pidruch dlia stud vyshch med navch zakl IV rivnia akredytatsii. Za red VH Maidannyka. Vinnytsia, Nova knyha: 879.
Marushko YuV, Marushko TV. 2011. Farmakoterapiia zakhvoriuvan orhaniv dykhannia u ditei. Naukovo-informatsiinyi posibnyk. K, Pryvatna drukarnia FO-P Petryshyn H.M.: 469.
Marushko YuV. 2012. The application in the treatment of respiratory karbotsisteina pathology in children. Sovremennaya pediatriya. 4: 112—118.
Mizernitskiy YuL. 2002. Otharkivayuschie i mukoliticheskie sredstva v terapii bronholegochnyih zabolevaniy u detey. Rukovodstvo po farmakoterapii v pediatrii i detskoy hirurgii. Pod obsch red AD Tsaregorodtseva, VA Tabolina. T1. Farmakoterapiya v pediatricheskoy pulmonologii. Pod red SYu Kaganova. M, Medpraktika-M: 123–140.
Mizernitskiy YuL, Ermakova IN. 2007. Sovremennyie mukoaktivnyie preparatyi v terapii ostryih respiratornyih zabolevaniy u detey. Consilium medicum. 1; 9: 53—56.
Mihaylov IB. 2005. Osnovyi farmakoterapii detey i vzroslyih. Rukovodstvo dlya vrachey. M, AST; SPb, Sova.
Soloveva NA, Kulakova GA, Kurmaeva EA. 2013. Mukoaktivnaya terapiya pri lechenii ostryih respiratornyih infektsiy u detey. Prakt meditsina. 6(75): 191—198.
Ovcharenko SI. 2002. Mukoliticheskie (mukoregulyatornyie) preparatyi v lechenii hronicheskoy obstruktivnoy bolezni legkih. RMZh. 10(4): 153—157.
Ovchinnikov AYu, Panyakina MA. 2010. Polozhitelnyiy opyit kompleksnogo konservativnogo lecheniya ostrogo i hronicheskogo gaymorita v stadii obostreniya. Effektivnaya farmakoterapiya. Pulmonologiya i otorinolaringologiya. 2: 84—90.
Prakticheskaya pulmonologiya detskogo vozrasta (spravochnik). Pod red VK Tatochenko. 3-e izd. M. 2006: 22—118.
Marushko YuV. 2012. Primenenie karbotsisteina v terapii respiratornoy patologii u detey. Sovr pediatriya. 4(44).
Ryazantsev SV. 2005. Rol Flyuditeka (karbotsisteina) v mukoliticheskoy terapii verhnih dyihatelnyih putey i uha. Ros otorinolaringol. 6.
Samsyigina GA. 2000. Kak lechit kashel u detey. Lechaschiy vrach. 3.
Samsyigina GA, Buslaeva GN. 2007. Mesto mukoliticheskih sredstv v lechenii kashlya u detey. Cons Med Pediatriya (Pril). 2: 22—25.
Sinopalnikov AI. Mukoaktivnyie preparatyi i obostrenie hronicheskoy obstruktivnoy bolezni legkih (fokus na kabrotsistein). Farmateka. http://www.pharmateca.ru/ru/archive/article/8582.
Tarasova GD. 2005. Vliyanie Flyuditeka na vospalenie polosti nosa. Ros rinologIya. 2: 201.
Tarasova GD, Ivanova TV, Protasov PG. 2005. Flyuditek v lechenii vospalitelnyih zabolevanii verhnih dyihatelnyih putey. Ros otorinolaringologiya. 6(19): 77—81.
Tatochenko VK. 2008. Differentsialnaya diagnostika kashlya u detey i ego lechenie. Lechaschiy vrach. 3.
Shmelev EI. 2009. Kashel pri vospalitelnyih zabolevaniyah legkih: diagnostika i lechenie. M.
Shuganov EG, Shelest EA, Gneusheva TYu, Salmasi ZhM, Shuganov AE. 2014. Mesto karbotsisteina v kompleksnoy terapii u bolnyih HOBL. Zemskiy Vrach. 1(22).
Yulish EI, Chernyisheva OE, Glinskaya EV. 2013. Differentsirovannyiy podhod k lecheniyu kashlya u detey. Zdorove rebenka. 1(44): 33—39.
Duijvestijn YC, Mourdi N, Smucny J et al. 2009, Jan. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database Syst Rev. 21(1): CD003124.
Allegra L, Cordaro CI, Grassi C. 1996. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Respiration. 63: 174—80.
Asada M, Yoshida M, Hatachi Y. 2012. L-carbocisteine inhibits respiratory syncytial virus infection in human tracheal epithelial cells. Respiratory Physiology and Neurobiology. 180(1): 112—118.
Asti C, Melillo G, Caselli GF et al. 1995. Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyperre-sponsiveness. Pharmacol Res. 31: 387—92.
Braga PC, Allegra L. 1989. Drugs in Bronchial Mucology. Raven Press.
Ishibashi Y, Takayama G, Inouye Y, Taniguchi A. 2010. Carbocisteine normalizes the viscous property of mucus through regulation of fucosylated and sialylated sugar chain on airway mucins. European Journal of Pharmacology. 641(2—3): 226—228.
Macci A, Madeddu C, Panzone F, Mantovani G. 2009. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opinion in Pharmacotherapy. 10(4): 693—703. http://dx.doi.org/10.1517/14656560902758343; PMid:19239402
Catalano GB, Mallanino N, Serra A. 1981. La carbocisteina nella patologia flogistica cronica rinosinusale. Otorinolaringologia. 31: 1—11.
Kwon NH, Oh MJ, Min TH et al. 2006. Causes and clinical features of subacute cough. Chest. 129: 1142—1147
Chang AB, Widdicombe JG. 2007. Cough throughout life: children, adults and the senile. Pulm Pharmacol Ther. 20: 371—382.
Chezzi GL, Zanocco P, Arrigoni G. 1987, Sep. Valutazione control-lata di un mucoregolatore, la carbocisteina, in un gruppo di pazzienti affetti da rinopatie chroniche catarrali. La Carbocisteina Oggi.
Colombo B, Turconi P, Daffonchio L et al. 1994. Stimulation of Cl-secretion by the mucoactive drug S-carboxy-methylcysteinelysine salt in the isolated rabbit trachea. Euro Respir J. 7: 1622—1628.
Majima Y, Kurono Y, Hirakawa K et al. 2012. Efficacy of combined treatment with S-carboxymethylcysteine (carbocisteine) and clarithromycin in chronic rhinosinusitis patients without nasal polyp or with small nasal polyp. Auris Nasus Larynx. 39(1): 38—47. http://dx.doi.org/10.1016/j.anl.2011.04.015; PMid:21636230
Garavaglia ML, Bononi E, Dossena S et al. 2008. S-CMC-Lys protective effect on human respiratory cells during oxidative stress. Cell Physiol Biochem. 22: 455—464.
Glezen WP. 2008. Modifying clinical practices to manage influenza in children effectively. Pediatr Infect Dis J. 27(8): 738—743. http://dx.doi.org/10.1097/INF.0b013e31816d9299
PMid:18664986
Goldsobel AB, Chipps BE. 2010. Cough in the Pediatric Population. The Journal of Pediatric. 156; 3: 352—358.
Guizzardi, Rodighiero S, Binelli A et al. 2006. S-CMC-Lysdependent stimulation of electrogenic glutathione secretion by human respiratory epithelium. J Mol Med. 84: 97—107.
Havez R, Degand P, Roussel P et al. 1970. Biochemical mechanism of action of cysteine derivatives on bronchial mucus. Poumon Coeur. 26: 81—90.
Hay AD, Heron J, Ness A. 2005. The prevalence of symptoms and consultations in preschool children in the Avon Longitudinal study of Parents and Children (ALSPAC): a prospective cohort study. Fam Pract. 22: 367—741.
Kumasava Т, Ushiro K. 1988. Clinical evaluatin of SCMC syrup applied in the treatmeht, lof otitis media with effusion. Acta Otolaringol (Stockh): 458, 456—462.
Maccio A, Madeddu C, Panzone F et al. 2009. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin Pharmacother. 10: 693—703.
Memoli MJ, Morens DM, Taubenberger JK. 2008. Pandemic and seasonal influenza: therapeutic challenges. Drug Discov Today. 13 (13—14): 590—652
Puchelle E, Girard F, Polu JM et al. 1978. Effect of the mucoregulator S-carboxy-methyl-cysteine in patients with chronic bronchitis. Eur J Clin Pharmacol. 14: 177—184.
Sahin-Yilmaz A, Naclerio RM. 2011. Anatomy and Physiology of the Upper Airway. Proc Am Thorac Soc. 8: 31—39.
Sumitomo T, Nakata M, Yamaguchi M et al. 2012. S-carboxymethylcysteine inhibits adherence of Streptococcus pneumoniae to human alveolar epithelial cells. Journal of Medical Microbiology. 61: 101—108.
Spingo G, Teatini GP. 1981. Valutazione dell 'efficacia della carbocisteina nel trattamentodelle otiti catarrali. Oto Rino Laring. 31: 1—4.
Spingo G, Teatini GP. 1977. L-impiego di un mucolitico orale nel trattamento dell otiti sieromucose. Nuevo Arch Ital 0 R L. 5: 115—122.
Suer E, Sayrac S, Sarinay E et al. 2008. Variation in attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S-carboxymethylcysteine. J Infect Chemother. 14: 333—336.
Tatsumi K, Fukuchi Y. 2007. Carbocysteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc. 55: 1884—1886.
Versteegh FG, Weverling GJ, Peeters MF et al. 2005. Community-acquired pathogens associated with prolonged cough in children: a prospective cohort study. Clin Microbiol Infect. 10: 801—807.
Yamaya M, Nishimura H, Shinya K. 2010. Inhibitory effects of carbocisteine on type A seasonal influenza virus infection in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 299(2): 160—168.
Yasuda H, Yamaya M, Sasaki T et al. 2006. Carbocysteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc. 54: 378—380.
Yasuda H, Yamaya M, Sazaki T et al. 2006. Carbocysteine inhibits rhinovirus infection in human tracheal epithelial cells. Eur Respir J. 28: 51—58.
Zheng Can Hong, Ahmed Kamruddin, Rikitomi Naoto, Martinez Glenda, Nagatake Tsuyoshi. 1999. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol and Immunol. 2; 43: 17—113.
Zheng JP, Kang J, Huang SG et al. 2008. Effect of carbocysteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo-controlled study. Lancet. 371: 2013—2018.
